A Randomized, Double-Blind Study of the Effect on Sustained Viral Response, and the Safety, of Standard or 360 ug PEGASYS [peginterferon alfa-2a] Induction Dosing in Combination With Standard or Higher Dose Copegus [ribavirin] in Treatment-Naive Chronic Hepatitis C Patients Weighing greater than 85kg With Genotype 1 High Viral Titer Infection.
Phase of Trial: Phase IV
Latest Information Update: 01 Mar 2013
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms PROGRESS
- 31 Aug 2018 Biomarkers information updated
- 26 May 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.
- 04 May 2010 Results have been presented at Digestive Disease Week (DDW) 2010.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History